Genedata Biologics streamlines Teva’s R&D workflows and increases operational efficiency
March 21, 2019
Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced that Teva Pharmaceuticals Inc. has chosen the Genedata Biologics® workflow platform to streamline the identification, engineering, and characterization of novel biopharmaceuticals drugs.
“We chose Genedata Biologics because its built-in business logic avoids costly software customization and it’s a proven off-the-shelf-product that can be implemented quickly and replace our current processes” said Dr. Adam Clarke, Senior Director, Teva Pharmaceuticals. “We also liked that it can be easily set-up to work with Teva’s workflows and technologies and that it’s an open system that can be integrated in Teva’s existing R&D and IT environment. Finally, we appreciate that the system is extendable and will scale with us as we grow.”
Teva will use Genedata Biologics as their backbone system across their antibody discovery operations. In addition, the platform will enable a thorough assessment of a drug candidate’s developability profile and facilitate handovers to the Teva development and manufacturing organization.
“We are excited to collaborate with Teva to enable them to increase the efficiency of their R&D processes,” said Dr. Othmar Pfannes, CEO of Genedata. “Our Biopharma Platform helps our customers bring cutting-edge therapeutics to patients faster, so they can live better and longer lives. Genedata is committed to continue our investment in the development of the Biopharma Platform and to provide our customers with an enterprise workflow platform that integrates and streamlines all biologics R&D processes.”
Teva Pharmaceutical Industries Ltd. is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 which are based on current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks and factors discussed in Teva's Annual Report on Form 10-K for the year ended December 31, 2018, including the sections thereof captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and Teva assumes no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.